News
-
8 February 2018
Immunocore Announces Leadership Change -
4 January 2018
Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-Executive Directors -
11 December 2017
Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma -
13 November 2017
Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate -
31 October 2017
Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting -
4 October 2017
Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer -
18 September 2017
Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases -
7 July 2017
Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK -
3 July 2017
Immunocore Announces Third Oncology Target Selected in Discovery Collaboration with GlaxoSmithKline -
5 June 2017
Immunocore Announces Compelling Single Agent IMCgp100 Clinical Data in Metastatic Uveal Melanoma at ASCO 2017 Annual Meeting